CERS
Price
$1.39
Change
-$0.04 (-2.82%)
Updated
Jun 30, 12:55 PM (EDT)
Capitalization
342.62M
31 days until earnings call
VCYT
Price
$27.19
Change
-$0.19 (-0.69%)
Updated
Jun 30, 04:43 PM (EDT)
Capitalization
1.66B
30 days until earnings call
Interact to see
Advertisement

CERS vs VCYT

Header iconCERS vs VCYT Comparison
Open Charts CERS vs VCYTBanner chart's image
Cerus
Price$1.39
Change-$0.04 (-2.82%)
Volume$204
Capitalization342.62M
Veracyte
Price$27.19
Change-$0.19 (-0.69%)
Volume$100
Capitalization1.66B
CERS vs VCYT Comparison Chart in %
Loading...
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VCYT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CERS vs. VCYT commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CERS is a Buy and VCYT is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (CERS: $1.42 vs. VCYT: $27.38)
Brand notoriety: CERS and VCYT are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CERS: 367% vs. VCYT: 350%
Market capitalization -- CERS: $342.62M vs. VCYT: $1.66B
CERS [@Medical Specialties] is valued at $342.62M. VCYT’s [@Medical Specialties] market capitalization is $1.66B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CERS’s FA Score shows that 0 FA rating(s) are green whileVCYT’s FA Score has 0 green FA rating(s).

  • CERS’s FA Score: 0 green, 5 red.
  • VCYT’s FA Score: 0 green, 5 red.
According to our system of comparison, CERS is a better buy in the long-term than VCYT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CERS’s TA Score shows that 5 TA indicator(s) are bullish while VCYT’s TA Score has 4 bullish TA indicator(s).

  • CERS’s TA Score: 5 bullish, 4 bearish.
  • VCYT’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, VCYT is a better buy in the short-term than CERS.

Price Growth

CERS (@Medical Specialties) experienced а +5.97% price change this week, while VCYT (@Medical Specialties) price change was +3.75% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +2.53%. For the same industry, the average monthly price growth was +2.42%, and the average quarterly price growth was +2.76%.

Reported Earning Dates

CERS is expected to report earnings on Jul 31, 2025.

VCYT is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Medical Specialties (+2.53% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VCYT($1.66B) has a higher market cap than CERS($343M). CERS YTD gains are higher at: -7.792 vs. VCYT (-30.859). CERS has higher annual earnings (EBITDA): -26.34M vs. VCYT (-49.41M). VCYT has more cash in the bank: 216M vs. CERS (65.9M). VCYT has less debt than CERS: VCYT (12.6M) vs CERS (96M). VCYT has higher revenues than CERS: VCYT (361M) vs CERS (156M).
CERSVCYTCERS / VCYT
Capitalization343M1.66B21%
EBITDA-26.34M-49.41M53%
Gain YTD-7.792-30.85925%
P/E RatioN/AN/A-
Revenue156M361M43%
Total Cash65.9M216M31%
Total Debt96M12.6M762%
FUNDAMENTALS RATINGS
CERS vs VCYT: Fundamental Ratings
CERS
VCYT
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
44
Fair valued
77
Overvalued
PROFIT vs RISK RATING
1..100
10096
SMR RATING
1..100
9686
PRICE GROWTH RATING
1..100
5560
P/E GROWTH RATING
1..100
10092
SEASONALITY SCORE
1..100
n/a95

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CERS's Valuation (44) in the Medical Specialties industry is somewhat better than the same rating for VCYT (77) in the Biotechnology industry. This means that CERS’s stock grew somewhat faster than VCYT’s over the last 12 months.

VCYT's Profit vs Risk Rating (96) in the Biotechnology industry is in the same range as CERS (100) in the Medical Specialties industry. This means that VCYT’s stock grew similarly to CERS’s over the last 12 months.

VCYT's SMR Rating (86) in the Biotechnology industry is in the same range as CERS (96) in the Medical Specialties industry. This means that VCYT’s stock grew similarly to CERS’s over the last 12 months.

CERS's Price Growth Rating (55) in the Medical Specialties industry is in the same range as VCYT (60) in the Biotechnology industry. This means that CERS’s stock grew similarly to VCYT’s over the last 12 months.

VCYT's P/E Growth Rating (92) in the Biotechnology industry is in the same range as CERS (100) in the Medical Specialties industry. This means that VCYT’s stock grew similarly to CERS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CERSVCYT
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
75%
Bullish Trend 4 days ago
86%
Momentum
ODDS (%)
Bullish Trend 4 days ago
72%
Bullish Trend 4 days ago
75%
MACD
ODDS (%)
Bearish Trend 4 days ago
82%
Bullish Trend 4 days ago
74%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
75%
Bullish Trend 4 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
75%
Bearish Trend 4 days ago
84%
Advances
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
74%
Declines
ODDS (%)
Bearish Trend 18 days ago
84%
Bearish Trend 18 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VCYT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EGLBX27.850.44
+1.61%
Elfun International Equity
SRIAX13.470.11
+0.82%
Gabelli SRI A
FDGCX21.120.16
+0.76%
Fidelity Advisor Dividend Growth C
FKMCX42.960.17
+0.40%
Fidelity Mid-Cap Stock K
JCVIX24.890.08
+0.32%
JHancock Classic Value I

CERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CERS has been loosely correlated with LAB. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then LAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CERS
1D Price
Change %
CERS100%
+4.41%
LAB - CERS
52%
Loosely correlated
-6.30%
NNOX - CERS
47%
Loosely correlated
-0.38%
SGHT - CERS
46%
Loosely correlated
+1.18%
UTMD - CERS
46%
Loosely correlated
+2.41%
BFLY - CERS
45%
Loosely correlated
-2.97%
More